NKG2A Down-Regulation by Dasatinib Enhances Natural Killer Cytotoxicity and Accelerates Effective Treatment Responses in Patients With Chronic Myeloid Leukemia

NKG2A Down-Regulation by Dasatinib Enhances Natural Killer Cytotoxicity and Accelerates Effective Treatment Responses in Patients With Chronic Myeloid Leukemia

Chronic myeloid leukemia (CML) is a hematological malignancy characterized by the presence of t(9;22) chromosomal translocation that results in BCR-ABL fusion gene. ABL tyrosine kinase inhibitors (TKIs), such as imatinib, nilotinib, and dasatinib, are currently the front-line treatment options for C...

Full description

Bibliographic Details
Main Authors:	Ming-Chin Chang, Hung-I Cheng, Kate Hsu, Yen-Ning Hsu, Chen-Wei Kao, Yi-Fang Chang, Ken-Hong Lim, Caleb Gonshen Chen
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2019-01-01
Series:	Frontiers in Immunology
Subjects:	CML BCR-ABL major molecular response (MMR) deep molecular response (DMR) natural killer cell NKG2A
Online Access:	https://www.frontiersin.org/article/10.3389/fimmu.2018.03152/full

Similar Items

In Silico Molecular Modeling of Four New Afatinib Derived Molecules Targeting the Inhibition of the Mutated Form of BCR-ABL T315I
by: Kelvyn M. L. Rocha, et al.
Published: (2024-09-01)

A study to determine the clinical, hematological, cytogenetic, and molecular profile in CML patient in and around Eastern UP, India
by: Sandip Kumar, et al.
Published: (2019-01-01)

Emergence role of nucleated red blood cells in molecular response evaluation for chronic myeloid leukemia
by: Phan TT, et al.
Published: (2019-09-01)

Chronic Myeloid Leukaemia with isolated massive thrombocytosis and BCR‐ABL1 detection failure using RT‐MLPA (positive RT‐qPCR)
by: Lucie Coster, et al.
Published: (2021-08-01)

Influence of late treatment on how chronic myeloid leukemia responds to imatinib
by: Ana Carolina Costa Scerni, et al.
Published: (2009-01-01)

Complete Molecular Response due to nilotinib as III line treatment in a patient with CML and F317L point mutation of the Bcr-Abl kinase domain
by: Maria Iovine, et al.
Published: (2015-10-01)

Frequency of BCR-ABL Fusion Transcript in Iranian Patients with Chronic Myeloid Leukemia
by: M Yaghmaie, et al.
Published: (2005-09-01)

Frequency of BCR-ABL Fusion Transcript in Iranian Patients with Chronic Myeloid Leukemia
by: Yaghmaie M., et al.
Published: (2005-09-01)

Immunological monitoring of newly diagnosed CML patients treated with bosutinib or imatinib first-line
by: Anna Kreutzman, et al.
Published: (2019-09-01)

Evaluation of 5‐year imatinib treatment of 458 patients with CP‐CML in routine clinical practice and prognostic impact of different BCR‐ABL cutoff levels
by: Hana Klamová, et al.
Published: (2013-04-01)

Methylenetetrahydrofolate Reductase Gene C677T and A1298C Polymorphic Sequence Variations Influences the Susceptibility to Chronic Myeloid Leukemia in Kashmiri Population
by: Shahid M. Baba, et al.
Published: (2019-07-01)

Association of BCR/ABL transcript variants with different blood parameters and demographic features in Iraqi chronic myeloid leukemia patients
by: Mahmood S. Khazaal, et al.
Published: (2019-08-01)

Monitoração molecular da Leucemia Mielóide Crônica na era do imatinibe Molecular monitoring of Chronic Myeloid Leukemia in the imatinib era
by: Israel Bendit
Published: (2008-04-01)

Does HOXA9 Gene Expression in Egyptian Chronic Myelogenous Leukemia Patients Affect Disease Progression? A Retrospective Cohort Study
by: Manar Mohamd Mohamad Ismail, et al.
Published: (2013-12-01)

Unveiling the nephrotoxic profile of BCR‐ABL tyrosine kinase inhibitors: A real‐world experience in Africa
by: Zekarias Seifu Ayalew, et al.
Published: (2024-08-01)

Effects of ABCG2 C421A and ABCG2 G34A genetic polymorphisms on clinical outcome and response to imatinib mesylate, in Iranian chronic myeloid leukemia patients
by: Negar Nouri, et al.
Published: (2023-01-01)

Extending the duration of response in chronic myelogenous leukemia: targeted therapy with sequential tyrosine kinase inhibitors
by: Michael G. Martin, et al.
Published: (2011-12-01)

Baseline blood count levels increase odds of cytopenia among CML patients in Kenya: a case control study
by: Angela McLigeyo, et al.
Published: (2022-02-01)

Diagnostic and therapeutic implications of genetic heterogeneity in myeloid neoplasms uncovered by comprehensive mutational analysis
by: Sarah M. Choi, et al.
Published: (2017-01-01)

Non ABL-directed inhibitors as alternative treatment strategies for chronic myeloid leukemia
by: Michele Massimino, et al.
Published: (2018-02-01)

The molecular mechanisms underlying BCR/ABL degradation in chronic myeloid leukemia cells promoted by Beclin1-mediated autophagy
by: Huang X, et al.
Published: (2019-06-01)

The Discovery of Novel BCR-ABL Tyrosine Kinase Inhibitors Using a Pharmacophore Modeling and Virtual Screening Approach
by: Ting-Ting Huang, et al.
Published: (2021-03-01)

DOWNREGULATION OF STEAROYL-COA DESATURASE 1 (SCD-1) PROMOTES RESISTANCE TO IMATINIB IN CHRONIC MYELOID LEUKEMIA
by: Buket Altinok Gunes, et al.
Published: (2023-01-01)

Molecular Pathogenesis and Treatment Strategies of Chronic Myeloid Leukemia (CML)
by: Rabia Khalid, et al.
Published: (2023-12-01)

The study of the impact of additional chromosomal aberrations and c-MYC and BCR::ABL1 genes amplification on CML patient’s characteristics: relation to haematological parameters and patient outcome
by: Hend Attia, et al.
Published: (2023-12-01)

Molecular diagnosis of bcr-abl fusion gene in CML patients using Monoplex-Two Steps- Reveres Transcriptase–Polymerase Chain
by: Maysaa A. Dhahii
Published: (2010-04-01)

Cross-talk between Bcr-abl and the Thioredoxin System in Chronic Myeloid Leukaemia: Implications for CML Treatment
by: Erin Clapper, et al.
Published: (2020-03-01)

Fusion gene bcr-abl: From etiopathogenesis to the management of chronic myeloid leukemia
by: Tri Agusti Sholikah
Published: (2017-04-01)

Ponatinib vs. asciminib in post–second-generation tyrosine kinase inhibitor therapy for chronic-phase chronic myeloid leukemia: a matching-adjusted indirect comparison
by: Valentin Garcia-Gutierrez, et al.
Published: (2024-11-01)

NKG2D/NKG2-Ligand Pathway Offers New Opportunities in Cancer Treatment
by: Alexandra Frazao, et al.
Published: (2019-03-01)

An In-house Method for Molecular Monitoring of BCR-ABL
by: Hakkı Ogun Sercan, et al.
Published: (2012-12-01)

Molecular Pathogenesis of BCR-ABL-Negative Atypical Chronic Myeloid Leukemia
by: Diletta Fontana, et al.
Published: (2021-11-01)

NPM1 MUTATED, BCR-ABL1 POSITIVE MYELOID NEOPLASMS: REVIEW OF LITERATURE
by: Gianfranco Catalano, et al.
Published: (2020-10-01)

PEG-Bottlebrush Stabilizer-Based Worm-like Nanocrystal Micelles with Long-Circulating and Controlled Release for Delivery of a BCR-ABL Inhibitor against Chronic Myeloid Leukemia (CML)
by: Huamin Liang, et al.
Published: (2022-08-01)

A novel BCR-ABL1 fusion gene with genetic heterogeneity indicates a good prognosis in a chronic myeloid leukemia case
by: Fen Zhou, et al.
Published: (2017-05-01)

Effect of Plumbagin on growth inhibition and apoptosis of imatinib-resistant chronic myeloid leukemia
by: Bui Thi Kim Ly, et al.
Published: (2017-08-01)

Case report: Long-term voluntary Tyrosine Kinase Inhibitor (TKI) discontinuation in chronic myeloid leukemia (CML): Molecular evidence of an immune surveillance
by: Jusuf Imeri, et al.
Published: (2023-03-01)

Future Approaches for Treating Chronic Myeloid Leukemia: CRISPR Therapy
by: Elena Vuelta, et al.
Published: (2021-02-01)

<i>Sphagneticola Trilobata</i> (L.) Pruski (Asteraceae) Methanol Extract Induces Apoptosis in Leukemia Cells through Suppression of BCR/ABL
by: Hoang Thanh Chi, et al.
Published: (2021-05-01)

A new aberrantly spliced BCR‐ABL1 transcript variant (e13a1) identified in routine monitoring using different quantitative reverse transcription polymerase chain reaction techniques in a patient with chronic myeloid leukemia
by: Nicole Naumann, et al.
Published: (2022-11-01)